NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Ardelyx, Inc. ARDX
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$407.3M
▲ 22.1% vs FY2024
EPS · FY25
$-0.26
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-36.2%
Net margin · FY25
-15.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 407.3M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 15 cents on every revenue dollar this year.
Per share
USD -0.26
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-36.2%
Return on equity, FY2025
ROE
Operating margin-10.1%
Net margin-15.1%
Return on assets-13.1%
Each USD of equity lost 36 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+121.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+98.4%
+121.9%
+32.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.24B
Shares outstanding, FY2025
Change, 5 years+175.2%
Change, 10 years—
The share count grew 175% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 501.6M
total assets, end of FY2025
Total assetsUSD 501.6M
EquityUSD 166.9M
CashUSD 68.0M
Gross debtUSD 202.8M
Net debtUSD 134.8M
Current ratio4.31×
Net debt stands at 81% of equity.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.4
0.3
0.1
0.1
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
0.0
0.0
·
Net income $B
−0.1
−0.0
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.26
−0.17
−0.30
−0.42
−1.52
−1.05
−1.47
−1.62
−1.36
−2.80
−1.29
−0.31
−5.82
−11.32
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−36.2
−23.0
−49.8
−74.3
−151.6
−60.3
−62.8
−71.6
−38.7
−74.4
−34.9
·
·
·
Shares out B
0.24
0.24
0.23
0.20
0.13
0.09
0.09
0.06
0.05
0.05
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed